The U.S. Food and Drug Administration has approved Addyi (flibanserin) – making it the first and only drug designed to help increase women's sexual desire. Mayo Clinic Women's Health Clinic director Stephanie Faubion, M.D., says while Addyi won't benefit every woman, it will offer a much-needed treatment option to help premenopausal women with hypoactive sexual desire disorder, or HSDD.
Dr. Faubion says about 40 percent of women in the United States report some type of problem with sexual function. She says many factors can be attributed to a low libido, including biological, psychological, relational and cultural issues. "This is a huge problem that causes relationship and personal distress. It's a problem that not only affects the woman but the couple."
Click here for more information about common changes in female sexuality around menopause.
Journalists: Sound bites available in the downloads. [TRT 1:38]